| Followers | 24 |
| Posts | 1403 |
| Boards Moderated | 0 |
| Alias Born | 01/27/2021 |
Wednesday, April 13, 2022 2:07:49 PM
I'm not a doctor but I agree with CaptBeer on this one.
I'm in my 60s and my eye doctor tried to get me to take fish oil supplements or Lovaza for eyelid inflammation, whatever that is. When I asked for Vascepa instead, he of course didn't know what it was. I think I told people on this board this story and got some "find a new doctor" comments. But with only 30,000 of 750,000 doctors in the U.S. ever having prescribed it and only 6,000 to 8,000 doing so regularly, it's hard to find doctors who prescribe Vascepa, even if they've heard of it. Especially so with eye doctors.
So if what JT said is true _ that Vascepa has the safety profile of aspirin _ doctors should be more willing to readily prescribe it off-label. Didn't JT once say that more than 50 percent of people on Vascepa were prescribed off-label? Although the studies either haven't been done or haven't been extensive enough to get an expanded label, shouldn't people want to get on Vascepa to reduce plaque in arteries, possibly fight Alzheimer's and generally lower inflammation throughout the body? And that's aside from what it does to reduce changes of heart attacks and strokes.
I'm in my 60s and my eye doctor tried to get me to take fish oil supplements or Lovaza for eyelid inflammation, whatever that is. When I asked for Vascepa instead, he of course didn't know what it was. I think I told people on this board this story and got some "find a new doctor" comments. But with only 30,000 of 750,000 doctors in the U.S. ever having prescribed it and only 6,000 to 8,000 doing so regularly, it's hard to find doctors who prescribe Vascepa, even if they've heard of it. Especially so with eye doctors.
So if what JT said is true _ that Vascepa has the safety profile of aspirin _ doctors should be more willing to readily prescribe it off-label. Didn't JT once say that more than 50 percent of people on Vascepa were prescribed off-label? Although the studies either haven't been done or haven't been extensive enough to get an expanded label, shouldn't people want to get on Vascepa to reduce plaque in arteries, possibly fight Alzheimer's and generally lower inflammation throughout the body? And that's aside from what it does to reduce changes of heart attacks and strokes.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
